On March 17, 2021, Merck announced that it had filed a Form 10 registration statement with the U.S. Securities and Exchange Commission in order to spinoff its women’s health, biosimilars and established brands businesses into a standalone, publicly traded company, named Organon. Merck explained that Organon’s vision is to “create a better and healthier every day for every woman around the globe.” Merck also announced that Carrie Cox will serve as chairman of the majority-female Board, which will consist of many individuals having CEO experience and who represent the fields of medicine, public health, business and technology. Carrie Cox explained, “[t]he representation of women on the Board — comprising 70% of positions — is higher than any S&P 500 healthcare company, focusing on Organon’s goal of making a positive impact on the global health of women.”
